{
    "nct_id": "NCT03369223",
    "official_title": "A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors",
    "inclusion_criteria": "* Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists\n* Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants\n* Willing and able to comply with all study procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded\n* Other active malignancy requiring concurrent intervention\n* Prior organ allograft\n* Active, known, or suspected autoimmune disease\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}